Groningen

• Neo-adjuvant Pembrolizumab in vulvar squamous cell carcinoma: a clinical proof-of-concept study Ended
  2024-512862-32-00 4 2023-05-11 Vulvar squamous cell carcinoma
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• A study in healthy men to test how BI 764198 is processed in the body Ended
  2022-502327-22-00 3 2023-05-03 Healthy
• A study in healthy men to test how BI 1291583 is processed in the body Ended
  2022-502264-20-00 3 2023-04-26 Healthy
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s Disease Ended
  2023-503203-29-00 3 2023-04-12 Parkinson's Disease
• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel … Ended
  2023-509243-27-00 4 2023-04-12 Moderate-to-Severe Uncontrolled Asthma
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ANDMULTIPLE … Ended
  2024-517955-10-00 1 2023-04-05 Healthy volunteers
• Safety and Tolerability of AC01 in patients with heart failure Ended
  2022-500347-20-00 9 2023-02-23 Heart Failure
• A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219 Ended
  2024-515744-23-00 1 2023-02-15 Relapsed or refractory (R/R) Acute lymphoblastic leukemia (ALL), R/R A
• SAD/MAD study with PTC844 Ended
  2022-501986-38-00 1 2022-12-30 Auto immune disorders
• An Open-label, Randomized, Three-period, Crossover Study to compare the Pharmacokinetics of GB1211 upon dosing a capsule under fasting condi … Ended
  2022-502200-67-00 3 2022-12-27 Non-small Cell Lung Cancer
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• ANISE-II; ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, d … Ended
  2024-516770-29-00 4 2022-10-09 Sjogren's disease
• A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Ended
  2023-504400-29-00 1 2022-09-15 Advanced malignancies.
• Personalized dosing of immunosuppression after kidney transplantation by measuring the immune system functionality Ended
  2022-500024-30-00 4 2022-08-23 Post Kidney transplantation
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk … Ended
  2023-508357-58-00 7 2022-07-04 Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myel
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPD Ended
  2024-512007-39-00 4 2022-06-20 Chronic Obstructive Pulmonary Disease
• A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination … Ended
  2024-511352-41-00 3 2022-06-13 advanced solid tumors
• A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended
  2023-508645-40-00 10 2022-05-10 Bullous Pemphigoid (BP)
• Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer Ended
  2024-512639-58-00 7 2022-05-07 Solid Tumors

Showing 601–624 of 679 trials